Title:	Randomized, double-blind study of stibogluconate plus human granulocyte macrophage colony-stimulating factor versus stibogluconate alone in the treatment of cutaneous Leishmaniasis
Authors:	Almeida, Roque Pacheco de D'Oliveira Júnior, Argemiro Machado, Paulo Roberto Lima Bacellar, Maria Olívia Amado Ramos Ko, Albert Icksang Jesus, Amélia Maria Ribeiro de Mobashery, N Santos, Jussamara Brito Carvalho Filho, Edgar Marcelino
Affilliation:	Hospitalar Universitário Professor Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil Hospitalar Universitário Professor Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil Hospitalar Universitário Professor Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil Hospitalar Universitário Professor Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil Cornell University Medical College. NY Hospital. Division of International Health and Infectious Diseases. Department of Medicine. New York, NY Hospitalar Universitário Professor Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil Cornell University Medical College. NY Hospital. Division of International Health and Infectious Diseases. Department of Medicine. New York, NY Hospitalar Universitário Professor Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil Hospitalar Universitário Professor Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil
Abstract:	The response to recombinant human granulocyte macrophage colony-stimulating factor (GM-CSF) in the treatment of cutaneous leishmaniasis was evaluated. Twenty patients with cutaneous leishmaniasis who had lesions for 60 days were enrolled in a double-blind placebo trial of GM-CSF with standard parenteral sodium stibogluconate (20 mg/kg-1/day-1) for 20 days. Ten patients were randomized to receive intralesionally injected GM-CSF (200 microgram) at enrollment and 1 week after, and 10 patients received saline as placebo. GM-CSF- and antimony-treated patients healed faster than patients who received antimony alone (49+/-32.8 vs. 110+/-61.6 days, P<.05). Seven of 10 patients were healed of their lesions before 40 days after therapy in the GM-CSF group, compared with only 1 of 10 patients in the placebo group (relative risk, 7; 95% confidence interval, 1.04-47.00). Thus, GM-CSF plus antimony significantly increased the chance of lesion healing in 40 days.
Keywords:	Leishmaniasis, Cutaneous Antimony Sodium Gluconate Antiprotozoal Agents Granulocyte-Macrophage Colony-Stimulating Factor Child Humans
keywords:	Leishmaniose cutânea Gluconato de antimônio e sódio Agentes antiprotozoários Fator Estimulador de Colônia de Granulócitos Criança Humanos
Issue Date:	1999
Publisher:	Oxford University Press
Citation:	ALMEIDA, R. P. et al. Randomized, double-blind study of stibogluconate plus human granulocyte macrophage colony-stimulating factor versus stibogluconate alone in the treatment of cutaneous Leishmaniasis. Journal of Infectious Diseases, v. 180, p. 1735–1737, 1999.
Description:	Ko, Albert Icksang “Documento produzido em parceria ou por autor vinculado à Fiocruz, mas não consta à informação no documento”.
DOI:	10.1086/315082
ISSN:	0022-1899
Copyright:	open access
Appears in Collections:	BA - IGM - Artigos de Periódicos

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.